The Selective Bruton’s Tyrosine Kinase (BTK) Inhibitor TG-1701 as Monotherapy and in Combination with Ublituximab and Umbralisib (U2) in Patients with B-cell Malignancies

Drug Category : Array
Conference Category : Array
Lead Author : Cheah C, et al.
Published Date : 11/12/2021
Download Link : https://www.tgtherapeutics.com/wp-content/uploads/2021/12/ASH2021Cheah1701.pdf
Download Text : Download
Popup Confirmation? :
site-sidebar-layout : default
ast-site-content-layout : default
site-content-style : default
site-sidebar-style : default
theme-transparent-header-meta : default
stick-header-meta : default
astra-migrate-meta-layouts : set
Scroll to Top